Phase 2 osimertinib EGFR inhibitor plus cyclosporine A calcineurin/NFAT inhibitor in EGFR-mutant NSCLC
Trial status
Currently Recruiting
Status as of
Got an update?- Trial ID
- NCT07874490 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer (NSCLC)
- Stage of research
- Exploratory
- Location
- New York, NY
- Published in
- New in Oncology - Nov 12, 2026
NYU Langone Health’s OCEAN trial is a single-site, biomarker-enriched, randomized, open-label Phase 2 study testing whether adding cyclosporine A (CsA) can deepen responses to osimertinib in metastatic EGFR-mutant NSCLC (exon 19 deletion or L858R). All consented patients who are ctDNA-positive at baseline receive a 3-week osimertinib run-in; those with persistent ctDNA (“shedders”) are randomly assigned 1:1 to continue AstraZeneca’s osimertinib (an irreversible, mutant-selective EGFR tyrosine kinase inhibitor) alone versus osimertinib plus CsA (a calcineurin inhibitor that suppresses NFAT signaling; used clinically as an immunosuppressant). Serial plasma ctDNA is collected about every 3 weeks to track molecular clearance, with imaging performed per usual care. The scientific angle is the ctDNA-guided “run-in → randomize only molecular non-responders” design, aiming to intensify therapy only for early resistant disease signals rather than treating everyone up front. Today’s care for first-line metastatic EGFR exon19/L858R NSCLC is osimertinib monotherapy, osimertinib with platinum/pemetrexed, or amivantamab plus lazertinib, followed by chemotherapy and/or targeted options at progression.
More in non-small cell lung cancer
-
New trial · Nov 19, 2026 · NCT07756645
Phase 3 ABBV-1480 PD-1×VEGF bispecific antibody vs pembrolizumab in 1L sqNSCLC -
New trial · Nov 19, 2026 · NCT07393555
Phase 2 sacituzumab govitecan (TROP2 ADC) ± ivonescimab (PD-1×VEGF bispecific) in AGA+ NSCLC -
New trial · Nov 19, 2026 · NCT07899801
Phase 1a/1b zanidatamab (HER2 bispecific antibody) + zongertinib (HER2 TKI) in HER2-mutated NSCLC -
New trial · Nov 12, 2026 · NCT07871214
Phase 2 pumitamig PD‑L1×VEGF‑A bispecific antibody neoadjuvant platform in resectable NSCLC. -
New trial · Nov 12, 2026 · NCT07864584
Phase 1/2 NHT102 inhaled azacitidine DNA hypomethylating agent (DNMT inhibitor) in NSCLC
